Sepsis is a potentially life-threatening complication due to presence of both infection and the systemic inflammatory response; it is caused by overwhelming immune response to infection. Sepsis is treated as a medical emergency, and severe case of sepsis may lead to septic shock, in which blood pressure reduces dramatically. It is estimated that the sepsis and septic shock treatment market will show significant market growth over the forecast period primarily due to growing number of target population, higher number of unmet needs, advancement in sepsis assessment techniques and presence of novel pipeline therapeutics.
The report titled "Sepsis and Septic Shock Treatment Market" - Growth, Future Prospects and Competitive Analysis, 2022- 2030 included in-depth analysis of sepsis and septic shock market for period of 2020 to 2030. This market report includes detailed study of market segments based on treatment type such as antimicrobial therapy (antibacterial drugs, antiviral drugs and antifungal drugs) and adjunctive therapy (mechanical ventilation, vasopressor therapy, fluid therapy, corticosteroids, blood transfusion, dialysis and insulin therapy).
For the purpose of the geographical study, the global sepsis and septic shock treatment market is categorized on the basis of key regional market such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For further regional and country level analysis, sepsis and septic shock treatment market is categorized into United States, Canada, Germany, United Kingdom, rest of Europe, Brazil, Mexico, Rest of LATAM, China, Japan, rest of APAC, GCC and rest of MEA.
Along with statistical information, in-depth qualitative information assessment tools are included in this study for better understanding about general market situation and future prospects. For understanding of ongoing trend of market and future market scenario, detail information regarding pipeline analysis, market drivers, challenges and opportunities in the global sepsis and septic shock treatment market are included in report. To provide in-depth information about the key players involve in sepsis and septic shock R&D activities, attractive investment proposition and company profiling section are also included in this report.
It is expected that the global sepsis and septic shock treatment market will show lucrative market growth majorly due to rising number of affected population, technological development in sepsis assessment, increase in research and development for developing sepsis treatments and expected launch of novel pipeline molecules over the forecast period. It is studied that antibacterial drugs among the antimicrobial therapies is the major revenue generating segment and anticipated to show fastest market growth during forecast period. Because bacteria such as Staphylococcus and Escherichia coli are the most common causes of sepsis. Furthermore, expected launch of pipeline drugs such as MDX 1105, CYT-107, ALT-836, LB-1148, IFX-1 etc. would assist market growth of sepsis drugs during forecast period. Broad-spectrum antibiotics are preferably used to initiate treatment as these are effective against a variety of bacteria. Currently, there is no approved regimen specific to treatment of sepsis but antimicrobials and adjunctive therapies are used to treat and management of sepsis. Previously, activated drotrecogin alfa (Xigris) was approved for sepsis, but has been voluntarily withdrawn by Eli Lilly in 2011 due to lack of efficacy.
Sepsis is a clinical condition caused by overwhelming inflammatory response to infection leading to multiple organ dysfunction. According to the Centers for Disease Control and Prevention (CDC), each year, more than 1.5 million people are affected with sepsis in the United States; 250,000 Americans die every year due to sepsis. It is observed that among the considered geographical markets, North America is currently dominating the global sepsis and septic shock treatment market and the growth is mainly driven by United States. Early diagnosis of disease, availability of developed techniques for sepsis assessment, wide accessibility to therapeutics, favorable government reimbursement policies, higher cost of therapeutics and well developed healthcare infrastructure are the important factors that are favoring the market dominance of North America. On the other hand, sepsis and septic shock treatment market in Asia Pacific will show the fastest market growth over the forecast period due to developing healthcare infrastructure, rising number of affected population and increasing penetration of key players in emerging countries such as China and India.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Sepsis And Septic Shock Treatment market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Sepsis And Septic Shock Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Treatment
- Antimicrobial Therapy
- Antibacterial Drugs
- Cephalosporins
- Macrolides
- Aminoglycosides
- Penicillins
- Lincosamides
- Quinolones
- Sulfonamides
- Glycopeptides
- Other
- Antiviral Drugs
- Antifungal Drugs
- Adjunctive Therapy
- Mechanical ventilation
- Vasopressor therapy
- Fluid Therapy
- Corticosteroids
- Blood transfusion
- Dialysis
- Insulin Therapy
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Sepsis And Septic Shock Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Sepsis And Septic Shock Treatment market?
- Which is the largest regional market for Sepsis And Septic Shock Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Sepsis And Septic Shock Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Sepsis And Septic Shock Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
Companies Mentioned
- Adrenomed AG
- Altor BioScience Corporation
- Asahi Kasei Pharma
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- InflaRx GmbH
- Inotrem SA
- Pfizer Inc.